Skip to main content

Table 1 Baseline characteristics of the EuroSIDA patients, included in the study after January 1 st , 2001 and according to the region of residence

From: Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study

  

SE

WCE

NE

ECE

EE

AR

p

  

1059

1290

923

1366

1964

495

 

N (% of total)

        

Gender

Male

799 (75.5)

992 (76.9)

702 (76.1)

968 (70.9)

1103 (56.2)

307 (62.0)

<.0001

Ethnic origin

White

952 (90.0)

911 (76.7)

749 (81.9)

1358 (99.6)

1958 (99.9)

488 (98.6)

<.0001

Exposure Group

Homosexual

7426 (40.2)

566 (43.9)

473 (51.3)

508 (37.2)

149 (7.6)

126 (25.5)

<.0001

 

IDU

188 (17.8)

128 (9.9)

86 (9.9)

345 (25.3)

923 (47.0)

62 (12.5)

 
 

Heterosexual

359 (33.9)

404 (31.3)

290 (31.4)

410 (30.0)

791 (40.3)

291 (58.8)

 

Treatment History

Naïve

253 (23.9)

183 (14.2)

145 (15.7)

259 (19.0)

1200 (61.1)

82 (16.6)

<.0001

 

cART

763 (72.0)

1035 (80.2)

744 (80.6)

1016 (74.4)

632 (32.2)

396 (80.0)

 

Hepatitis B surface antigen status

positive

45 (4.3)

58 (4.5)

35 (3.8)

60 (4.4)

107 (5.5)

26 (5.3)

.003

 

negative

827 (78.1)

996 (77.2)

742 (80.4)

1115 (81.6)

1562 (79.5)

357 (72.1)

 
 

unknown

187 (17.7)

236 (18.3)

146 (15.8)

191 (14.0)

295 (15.0)

112 (22.6)

 

Hepatitis C antibody status

positive

174 (16.4)

155 (12.0)

81 (8.8)

352 (25.8)

950 (48.4)

91 (18.4)

<.0001

 

negative

688 (65.0)

874 (67.8)

662 (71.6)

831 (60.8)

666 (33.9)

295 (59.6)

 
 

unknown

197 (18.6)

261 (20.2)

180 (19.5)

183 (13.4)

348 (17.7)

109 (22.0)

 

Previous AIDS diagnosis

yes

180 (17.0)

352 (27.3)

187 (20.3)

312 (19.9)

391 (19.9)

101 (32.5)

<.0001

Median (IQR)

       

Age

39 (33–46)

42 (36–49)

42 (36–50)

35 (29–42)

30 (26–36)

36 (31–43)

<.0001

CD4-cell count/mm3 1

434 (293–636)

447 (305–628)

432 (310–610)

369 (245–524)

415 (267–575)

346 (199–518)

<.0001

HIV-RNA (log10) copies/ml2

2.05 (1.70-4.08)

1.70 (1.70-3.33)

1.70 (1.60-3.28)

2.33 (1.70-3.79)

3.48 (2.60-4.58)

2.19 (1.70-4.00)

<.0001

Baseline date

1/06 (11/03-6/06)

1/06 (11/03-8/06)

1/06 (11/03-6/08)

11/05 (1/02-6/08)

1/06 (2/04-6/08)

2/06 (1/03-6/06)

<.0001

  1. Baseline date defined as the date of enrolment into the EuroSIDA study.
  2. IDU, injection drug user; cART, combination antiretroviral therapy; HIV-RNA, viral load;
  3. SE, Southern Europe: Greece, Israel, Italy, Portugal, Spain; WCE, West Central Europe: Austria, Belgium, France, South Germany, Luxembourg, Switzerland; NE, Northern Europe: Denmark, Finland, North Germany, Ireland, the Netherlands, Norway, Sweden, the United Kingdom; ECE, East Central Europe: Bulgaria, Croatia, the Czech Republic, Hungary, Poland, Romania, Serbia and Slovakia; EE, Eastern Europe: Belarus, Estonia, Latvia, Lithuania, the Russian Federation and the Ukraine; AR, Argentina.
  4. 1 N (%) CD4-cell count measurements were missing for 33 (3.1), 36 (2.8), 26 (2.8), 67 (4.69), 418(21.3) and 104 (21.0) in SE, WCE, NE, ECE, EE and AR respectively.
  5. 2 N (%) HIV-RNA measurements were missing for: 52 (4.9), 49 (3.8), 21 (2.3), 252 (18.5), 1289 (65.6) and 132 (26.7) in SE, WCE, NE, ECE, EE and AR respectively.